ERBB2 and breast carcinoma: All these immunological findings may partially explain the synergistic activity of trastuzumab and docetaxel in the treatment of HER2-overexpressing breast cancer and the excellent clinical outcome afforded by this combination in neoadjuvant setting (Guiu et al, 2011).